Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY)
CUSIP: 75943R102
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 4,389,099
- Total 13F shares
- 162,665,545
- Share change
- -484,005
- Total reported value
- $426,190,863
- Put/Call ratio
- 32%
- Price per share
- $2.62
- Number of holders
- 205
- Value change
- -$16,276,230
- Number of buys
- 106
- Number of sells
- 81
Quarterly Holders Quick Answers
What is CUSIP 75943R102?
CUSIP 75943R102 identifies RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 75943R102:
Top shareholders of RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD |
13F
|
Company |
636%
|
27,904,963
|
$114,968,448 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
342%
|
15,030,209
|
$61,924,461 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
14,674,262
|
$60,457,958 | — | 31 Dec 2024 | |
| Casdin Capital, LLC |
13F
|
Company |
204%
|
8,948,574
|
$36,868,125 | — | 31 Dec 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
184%
|
8,068,058
|
$33,240,399 | — | 31 Dec 2024 | |
| Bellevue Group AG |
13F
|
Company |
168%
|
7,377,292
|
$30,394,443 | — | 31 Dec 2024 | |
| NORGES BANK |
13F
|
Company |
132%
|
5,781,878
|
$23,821,337 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
120%
|
5,279,726
|
$21,752,471 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
113%
|
4,978,443
|
$20,511,186 | — | 31 Dec 2024 | |
| Nextech Invest Ltd. |
13F
|
Company |
88%
|
3,846,409
|
$15,847,205 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
76%
|
3,321,741
|
$13,687,000 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
69%
|
3,030,157
|
$12,487,108 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
68%
|
2,964,997
|
$12,216,150 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
62%
|
2,705,969
|
$11,148,592 | — | 31 Dec 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
61%
|
2,682,083
|
$11,050,182 | — | 31 Dec 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
59%
|
2,568,384
|
$10,581,742 | — | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
52%
|
2,268,825
|
$9,347,559 | — | 31 Dec 2024 | |
| Finepoint Capital LP |
13F
|
Company |
50%
|
2,175,646
|
$8,963,662 | — | 31 Dec 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
39%
|
1,729,199
|
$7,124,300 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
36%
|
1,592,753
|
$6,562,143 | — | 31 Dec 2024 | |
| Alphabet Inc. |
13F
|
Company |
36%
|
1,568,753
|
$6,463,263 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
35%
|
1,549,190
|
$6,382,663 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
32%
|
1,400,000
|
$5,768,000 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
30%
|
1,300,770
|
$5,359,174 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
27%
|
1,169,979
|
$4,820,314 | — | 31 Dec 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
26%
|
1,160,117
|
$4,779,682 | — | 31 Dec 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
25%
|
1,083,487
|
$4,463,966 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
23%
|
1,010,807
|
$4,164,525 | — | 31 Dec 2024 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
23%
|
1,000,000
|
$4,120,000 | — | 31 Dec 2024 | |
| Kynam Capital Management, LP |
13F
|
Company |
23%
|
1,000,000
|
$4,120,000 | — | 31 Dec 2024 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
23%
|
994,923
|
$4,099,000 | — | 31 Dec 2024 | |
| Trexquant Investment LP |
13F
|
Company |
22%
|
978,137
|
$4,029,924 | — | 31 Dec 2024 | |
| Walleye Capital LLC |
13F
|
Company |
21%
|
927,137
|
$3,819,804 | — | 31 Dec 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
19%
|
816,085
|
$3,362,270 | — | 31 Dec 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
16%
|
693,308
|
$2,856,429 | — | 31 Dec 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
16%
|
692,279
|
$2,852,189 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
16%
|
686,878
|
$2,829,937 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
15%
|
653,428
|
$2,692,123 | — | 31 Dec 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
15%
|
641,426
|
$2,642,675 | — | 31 Dec 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
15%
|
638,900
|
$2,632,268 | — | 31 Dec 2024 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
14%
|
623,339
|
$2,568,157 | — | 31 Dec 2024 | |
| BESSEMER GROUP INC |
13F
|
Company |
13%
|
584,463
|
$2,408,000 | — | 31 Dec 2024 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
13%
|
549,645
|
$2,264,537 | — | 31 Dec 2024 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
12%
|
541,124
|
$2,229,431 | — | 31 Dec 2024 | |
| Boxer Capital Management, LLC |
13F
|
Company |
12%
|
536,132
|
$2,208,864 | — | 31 Dec 2024 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
12%
|
505,778
|
$2,083,805 | — | 31 Dec 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
11%
|
500,548
|
$2,062,258 | — | 31 Dec 2024 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
10%
|
460,000
|
$1,895,200 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
10%
|
457,294
|
$1,884,052 | — | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
8.1%
|
354,500
|
$1,460,540 | — | 31 Dec 2024 |
Institutional Holders of Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) as of Q1 2025
As of 31 Mar 2025,
Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) was held by
205 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
162,665,545 shares.
The largest 10 holders included
SB INVESTMENT ADVISERS (UK) LTD, BlackRock, Inc., VANGUARD GROUP INC, Point72 Asset Management, L.P., Casdin Capital, LLC, TANG CAPITAL MANAGEMENT LLC, Bellevue Group AG, STATE STREET CORP, JPMORGAN CHASE & CO, and NORGES BANK.
This page lists
205
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
197
Q1 2025 holders
205
Holder diff
8
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.